Alumis Inc (ALMS)

$11.49 -0.12 (-1.03%)
Market Cap 1.20B
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 799,600
Avg Vol 1,016,942
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 81%
Beta -1.87
Analysts Strong Sell
Price Target $19.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
RapidFury
RapidFury Dec. 13 at 6:19 PM
ARBB broke out on Friday, Setting itself up for a parabolic move up. Keep it on that watchlist. They are sending all these micro float cap tickers on insane rallies recently. Would not even be shocked if they send ARBB for 500% next. Only 640k shares outstanding to buy 💎 Maybe $SPHL $ALMS $WAI $SOBR round 2
0 · Reply
AlphaAlpaca
AlphaAlpaca Dec. 12 at 5:39 AM
$ALMS Very healthy pullback as expected. Nothing has changed since my post below. Soon we will be piercing and holding that 13$+ level and then from there, on to new highs ⬆️ With upcoming catalysts, nothing holding us back. The Alpaca is holding strong!
2 · Reply
mlete21
mlete21 Dec. 11 at 8:50 PM
$ALMS here we grow!
0 · Reply
10xby3
10xby3 Dec. 11 at 8:17 PM
$ALMS more short covering in next 30 mins
0 · Reply
10xby3
10xby3 Dec. 11 at 4:22 PM
$ALMS buy dip and we keep rising
0 · Reply
10xby3
10xby3 Dec. 10 at 8:26 PM
$ALMS IYKYK $15 soon just wow!
1 · Reply
SlayinBulls
SlayinBulls Dec. 10 at 7:41 PM
$TRVI $ALMS $STTK Huge Insider Buying --> $MRAM $PEPG
1 · Reply
mlete21
mlete21 Dec. 10 at 7:08 PM
$ALMS we keep touching the $11.70! Let’s go $12!
0 · Reply
10xby3
10xby3 Dec. 10 at 1:46 PM
$ALMS lucky 13 coming today and we keep rising!
0 · Reply
AZOZ
AZOZ Dec. 10 at 1:16 PM
$MERC $KVHI $ALMS Insider love it right now!
0 · Reply
Latest News on ALMS
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 4 weeks ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 5 weeks ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 3 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 3 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 5 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 5 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 7 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 7 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 7 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 7 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 7 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 8 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 8 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 8 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 8 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 9 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 9 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 9 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 9 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 10 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 10 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 10 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 10 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 10 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 10 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 11 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 11 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 11 months ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

RapidFury
RapidFury Dec. 13 at 6:19 PM
ARBB broke out on Friday, Setting itself up for a parabolic move up. Keep it on that watchlist. They are sending all these micro float cap tickers on insane rallies recently. Would not even be shocked if they send ARBB for 500% next. Only 640k shares outstanding to buy 💎 Maybe $SPHL $ALMS $WAI $SOBR round 2
0 · Reply
AlphaAlpaca
AlphaAlpaca Dec. 12 at 5:39 AM
$ALMS Very healthy pullback as expected. Nothing has changed since my post below. Soon we will be piercing and holding that 13$+ level and then from there, on to new highs ⬆️ With upcoming catalysts, nothing holding us back. The Alpaca is holding strong!
2 · Reply
mlete21
mlete21 Dec. 11 at 8:50 PM
$ALMS here we grow!
0 · Reply
10xby3
10xby3 Dec. 11 at 8:17 PM
$ALMS more short covering in next 30 mins
0 · Reply
10xby3
10xby3 Dec. 11 at 4:22 PM
$ALMS buy dip and we keep rising
0 · Reply
10xby3
10xby3 Dec. 10 at 8:26 PM
$ALMS IYKYK $15 soon just wow!
1 · Reply
SlayinBulls
SlayinBulls Dec. 10 at 7:41 PM
$TRVI $ALMS $STTK Huge Insider Buying --> $MRAM $PEPG
1 · Reply
mlete21
mlete21 Dec. 10 at 7:08 PM
$ALMS we keep touching the $11.70! Let’s go $12!
0 · Reply
10xby3
10xby3 Dec. 10 at 1:46 PM
$ALMS lucky 13 coming today and we keep rising!
0 · Reply
AZOZ
AZOZ Dec. 10 at 1:16 PM
$MERC $KVHI $ALMS Insider love it right now!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 10 at 1:11 AM
$ALMS 15?! I think this goes to 30-40 with good data. 70 with excellent data.
2 · Reply
ELNINA
ELNINA Dec. 10 at 12:47 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 70,028 +6.12% $ 10.01 1,213,873 Dec 05, 2025 Dec 9, 2025 8:13 PM
0 · Reply
ELNINA
ELNINA Dec. 10 at 12:46 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 51,380 +4.23% $ 10.73 1,265,253 Dec 05, 2025 Dec 9, 2025 8:13 PM
0 · Reply
ELNINA
ELNINA Dec. 10 at 12:45 AM
$ALMS HE IS NOT DONE YET :) AKKARAJU SRINIVAS Not Specified Purchase 64,969 +6.02% $ 8.95 1,143,845 Dec 05, 2025 Dec 9, 2025 8:13 PM
0 · Reply
10xby3
10xby3 Dec. 9 at 7:57 PM
$ALMS shorts getting liquidated
1 · Reply
10xby3
10xby3 Dec. 9 at 6:29 PM
$ALMS next leg up from here
1 · Reply
JFais
JFais Dec. 7 at 7:17 PM
$ALMS- appreciated Larry's take on this aspiring immunology player
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 7 at 3:22 PM
$TERN $ALMS $PRME $ALT $CAPR 1 month check up. How am I doing?
1 · Reply
topstockalerts
topstockalerts Dec. 7 at 2:57 PM
Fridays Top Gainers PT2 $LICN $SPHL $ALMS $WAI $SOBR
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 6 at 9:13 PM
$ALMS insiders buying tutes probably loading. Very little retail.
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Dec. 6 at 8:35 PM
What happened with $ALMS on Friday?
0 · Reply
topstockalerts
topstockalerts Dec. 6 at 2:04 PM
Top Gainers PT2 $LICN $SPHL $ALMS $WAI $SOBR
1 · Reply